Shah S, Nawaz HS, Qazi MS, Jain H, Lucke-Wold B. Living biodrugs and how tissue source influences mesenchymal stem cell therapeutics for heart failure. World J Cardiol 2024; 16(11): 619-625 [DOI: 10.4330/wjc.v16.i11.619]
Corresponding Author of This Article
Siddharth Shah, MBBS, Postdoctoral Fellow, Lillian S Wells Department of Neurosurgery, University of Florida, 1505 SW Archer Road, Gainesville, FL 32608, United States. siddharth.dr99@gmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Siddharth Shah, Brandon Lucke-Wold, Lillian S Wells Department of Neurosurgery, University of Florida, Gainesville, FL 32608, United States
Huzaifa Sabir Nawaz, Department of Internal Medicine, Services Institute of Medical Sciences, Lahore 54000, Pakistan
Muhammad Saeed Qazi, Department of Internal Medicine, Bilawal Medical College for Boys, Jamshoro 54000, Pakistan
Hritvik Jain, Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur 400022, India
Co-corresponding authors: Siddharth Shah and Brandon Lucke-Wold.
Author contributions: Shah S, Nawaz HS, Qazi MS, Jain H, and Lucke-Wold B conceptualized and designed the research; Shah S, Nawaz HS screened articles and acquired clinical data; Shah S, Nawaz HS, Qazi MS, Jain H, and Lucke-Wold B wrote the paper. All the authors have read and approved the final manuscript. Shah S, Nawaz HS, Qazi MS, Jain H, and Lucke-Wold B prepared the first draft of the manuscript. Shah S and Lucke-Wold B conceptualized, designed, and supervised the whole process of the project. They searched the literature, revised and submitted the early version of the manuscript. Shah S, Nawaz HS, Qazi MS and Jain H prepared the figures and table.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Siddharth Shah, MBBS, Postdoctoral Fellow, Lillian S Wells Department of Neurosurgery, University of Florida, 1505 SW Archer Road, Gainesville, FL 32608, United States. siddharth.dr99@gmail.com
Received: August 22, 2024 Revised: September 21, 2024 Accepted: October 20, 2024 Published online: November 26, 2024 Processing time: 69 Days and 13.9 Hours
Abstract
In this editorial we comment on the article by Safwan M et al. We especially focused on the cardiac function restoration by the use of mesenchymal stem cells (MSCs) therapy for heart failure (HF), which has emerged as a new treatment approach as “Living Biodrugs”. HF remains a significant clinical challenge due to the heart’s inability to pump blood effectively, despite advancements in medical and device-based therapies. MSCs have emerged as a promising therapeutic approach, offering benefits beyond traditional treatments through their ability to modulate inflammation, reduce fibrosis, and promote endogenous tissue regeneration. MSCs can be derived from various tissues, including bone marrow and umbilical cord. Umbilical cord-derived MSCs exhibit superior expansion capabilities, making them an attractive option for HF therapy. Conversely, bone marrow-derived MSCs have been extensively studied for their potential to improve cardiac function but face challenges related to cell retention and delivery. Future research is focusing on optimizing MSC sources, enhancing differentiation and immune modulation, and improving delivery methods to overcome current limitations.
Core Tip: Mesenchymal stem cells (MSCs) offer a novel regenerative approach to treating heart failure (HF), especially ischemic HF, by modulating inflammation, reducing fibrosis, and promoting tissue repair. Sources like bone marrow and umbilical cord each provide distinct benefits. Umbilical cord-derived MSCs are particularly promising due to their superior growth capacity and reduced senescence. However, challenges in cell retention and delivery persist. Current research focuses on refining MSC sources, enhancing differentiation, and improving delivery methods, paving the way for MSCs to become a pivotal therapy in HF management.
